A consortium of European researchers has received nearly 15 million euros in European Commission funding to study chronic inflammatory diseases, including systemic lupus erythematosus. The goal is to develop treatments that target the root causes of the diseases. The grant, the equivalent of $16 million, is also aimed at developing…
The prevalence of human papillomavirus (HPV) infections may increase over time among women with systemic lupus erythematosus (SLE), but more studies are needed to assess the group’s risk, a new study says. The study, “Incidence Of Cervical Human Papillomavirus Infection In Systemic Lupus Erythematosus Women,” was published in the…
Frailty, a syndrome of weight loss, weakness, slowness, exhaustion and inactivity, may predict reduced physical and cognitive function and a high risk of mortality in women with systemic lupus erythematosus. Patricia P. Katz, PhD, of the University of California, San Francisco School of Medicine, reported these findings at the 2016…
The cancer drug Vecade (bortezomib) combined with glucocorticoids could be a treatment option for people with drug-resistant lupus nephritis (LN), suggests a study published in the scientific journal Lupus.
Childhood-onset systemic lupus erythematosus (cSLE) may be linked to the development of eye problems such as uveitis that can cause blindness, a study says. The research, “Uveitis In Childhood-Onset Systemic Lupus Erythematosus Patients: A Multicenter Survey,” was published in the journal Clinical Rheumatology. Nearly a third of SLE…
Cytori Therapeutics will expand the scope of its Habeo Cell Therapy (ECCS-50) for secondary Raynaud’s phenomenon to include patients with systemic lupus erythematosus and other autoimmune conditions in addition to scleroderma patients. It made the decision after a pilot trial (NCT01813279) of the cell therapy helped 12 scleroderma patients…
Sanofi will work with ImmuNext to develop INX-021, a CD40L monoclonal antibody designed to suppress overactive cell signals associated with autoimmune disorders, including lupus and multiple sclerosis. Under the agreement, Sanofi will have an exclusive license to further develop and commercialize INX-021, a synthetic antibody from ImmuNext that is now in preclinical…
Vaccinating systemic lupus erythematosus (SLE) patients with attenuated T-cells improved their symptoms, according to results of a small controlled trial. It supported previous findings that the vaccination can help lupus patients. The study, “The Impact of T Cell Vaccination in Alleviating and Regulating Systemic Lupus Erythematosus Manifestation,” was…
A retrospective study of lupus myocarditis (LM) in systemic lupus erythematosus (SLE) patients found that, while the disease initially is severe, its long-term outcomes generally are very good. The results were published in the Journal of Rheumatology in the article, “Lupus…
Systemic lupus erythematosus (SLE) patients with signs of organ damage when first hospitalized, even if they don’t have active disease, are likely to have poorer outcomes, researchers in China reported. Mortality risk was particularly high in SLE patients with neuropsychiatric and cardiopulmonary complications or with evidence of kidney failure. But…